Does Rallies show 13F holders for RGNX?

Yes. Rallies tracks hedge fund and 13F ownership data for RGNX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RGNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RGNX. It does not provide personalized investment advice.

RGNX (REGENXBIO Inc.) Stock Analysis - Hedge Fund Holdings

REGENXBIO Inc. (RGNX) is a publicly traded Healthcare sector company. As of May 20, 2026, RGNX trades at $5.99 with a market cap of $292.09M and a P/E ratio of -1.04. RGNX moved +5.12% today. Year to date, RGNX is -55.45%; over the trailing twelve months it is -40.30%. Its 52-week range spans $5.04 to $16.19. Analyst consensus is strong buy with an average price target of $21.69. Rallies surfaces RGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RGNX stock?

Hedge funds tracked by Rallies that own RGNX include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for REGENXBIO Inc..

RGNX Key Metrics

Key financial metrics for RGNX
Metric	Value
Price	$5.99
Market Cap	$292.09M
P/E Ratio	-1.04
EPS	$-5.60
Dividend Yield	0.00%
52-Week High	$16.19
52-Week Low	$5.04
Volume	2.06M
Avg Volume	0
Revenue (TTM)	$87.82M
Net Income	$-290.01M
Gross Margin	0.00%

Top Hedge Funds Holding RGNX

Redmile Group holds 4.37M shares of RGNX, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 102.14K shares of RGNX, changed -54.14% as of Mar 31, 2026.

Latest RGNX News

Regenxbio Shares Plunge 37.8% to $6.25 After RGX-202 Trial Data Release — May 14, 2026
Regenxbio Q1 Loss Widens to $90M as RGX-202 Trial Hits 93% Endpoint — May 14, 2026
REGENXBIO's RGX-202 Achieves 93% Microdystrophin Expression, Eyes Accelerated 2027 Approval — May 14, 2026
Regenxbio Sets May 14 Webcast to Unveil RGX-202 Trial Results and Q1 Financials — May 6, 2026
REGENXBIO Sees +4.9-Point NSAA Gain, Stable LVEF in Phase I/II Trial — Mar 11, 2026

Recent RGNX Insider Trades

PAKOLA STEVE sold 15.31K (~$168.71K) on May 11, 2026.
PAKOLA STEVE sold 5.12K (~$53.03K) on Mar 10, 2026.
Simpson Curran sold 20.81K (~$262.63K) on Oct 9, 2025.

RGNX Analyst Consensus

9 analysts cover RGNX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.69.

Common questions about RGNX

Who owns RGNX stock?: Hedge funds tracked by Rallies that own RGNX include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for REGENXBIO Inc..
Does Rallies show 13F holders for RGNX?: Yes. Rallies tracks hedge fund and 13F ownership data for RGNX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RGNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RGNX. It does not provide personalized investment advice.